↓ Skip to main content

Advances, challenges and future directions for stem cell therapy in amyotrophic lateral sclerosis

Overview of attention for article published in Molecular Neurodegeneration, November 2017
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#28 of 768)
  • High Attention Score compared to outputs of the same age (93rd percentile)
  • High Attention Score compared to outputs of the same age and source (97th percentile)

Mentioned by

news
3 news outlets
twitter
15 tweeters

Citations

dimensions_citation
39 Dimensions

Readers on

mendeley
147 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Advances, challenges and future directions for stem cell therapy in amyotrophic lateral sclerosis
Published in
Molecular Neurodegeneration, November 2017
DOI 10.1186/s13024-017-0227-3
Pubmed ID
Authors

Yuri Ciervo, Ke Ning, Xu Jun, Pamela J. Shaw, Richard J. Mead

Abstract

Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative condition where loss of motor neurons within the brain and spinal cord leads to muscle atrophy, weakness, paralysis and ultimately death within 3-5 years from onset of symptoms. The specific molecular mechanisms underlying the disease pathology are not fully understood and neuroprotective treatment options are minimally effective. In recent years, stem cell transplantation as a new therapy for ALS patients has been extensively investigated, becoming an intense and debated field of study. In several preclinical studies using the SOD1(G93A) mouse model of ALS, stem cells were demonstrated to be neuroprotective, effectively delayed disease onset and extended survival. Despite substantial improvements in stem cell technology and promising results in preclinical studies, several questions still remain unanswered, such as the identification of the most suitable and beneficial cell source, cell dose, route of delivery and therapeutic mechanisms. This review will cover publications in this field and comprehensively discuss advances, challenges and future direction regarding the therapeutic potential of stem cells in ALS, with a focus on mesenchymal stem cells. In summary, given their high proliferation activity, immunomodulation, multi-differentiation potential, and the capacity to secrete neuroprotective factors, adult mesenchymal stem cells represent a promising candidate for clinical translation. However, technical hurdles such as optimal dose, differentiation state, route of administration, and the underlying potential therapeutic mechanisms still need to be assessed.

Twitter Demographics

The data shown below were collected from the profiles of 15 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 147 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 147 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 30 20%
Student > Master 16 11%
Researcher 15 10%
Student > Ph. D. Student 15 10%
Other 9 6%
Other 20 14%
Unknown 42 29%
Readers by discipline Count As %
Neuroscience 25 17%
Medicine and Dentistry 23 16%
Biochemistry, Genetics and Molecular Biology 19 13%
Agricultural and Biological Sciences 9 6%
Nursing and Health Professions 5 3%
Other 21 14%
Unknown 45 31%

Attention Score in Context

This research output has an Altmetric Attention Score of 40. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 August 2019.
All research outputs
#739,008
of 20,168,546 outputs
Outputs from Molecular Neurodegeneration
#28
of 768 outputs
Outputs of similar age
#20,780
of 334,465 outputs
Outputs of similar age from Molecular Neurodegeneration
#3
of 85 outputs
Altmetric has tracked 20,168,546 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 768 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.3. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 334,465 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 85 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.